Chisato Ashida

ORCID: 0000-0003-3137-0138
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Renal Diseases and Glomerulopathies
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Vasculitis and related conditions
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Myeloid Leukemia Treatments
  • Asthma and respiratory diseases
  • IgG4-Related and Inflammatory Diseases
  • HER2/EGFR in Cancer Research
  • Dermatology and Skin Diseases
  • Parasites and Host Interactions
  • Psoriasis: Treatment and Pathogenesis
  • Immune Cell Function and Interaction
  • Systemic Sclerosis and Related Diseases
  • T-cell and Retrovirus Studies
  • Eosinophilic Esophagitis
  • Abdominal vascular conditions and treatments
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Galectins and Cancer Biology
  • Viral Infections and Immunology Research
  • Otitis Media and Relapsing Polychondritis

Kindai University
2018-2025

While targeting the interleukin-6 receptor (IL-6R) through use of sarilumab (SAR) or tocilizumab (TCZ) has become a major therapeutic approach for rheumatoid arthritis (RA), direct comparisons between IL-6R inhibitors (IL-6Ris) treating RA have not been conducted. We aimed to compare effectiveness subcutaneous (SAR-SC), (TCZ-SC), and intravenous TCZ (TCZ-IV) against in multicenter cohort study. Within target trial emulation framework, an incident new-user active-comparator design was used....

10.1186/s13075-025-03514-x article EN cc-by-nc-nd Arthritis Research & Therapy 2025-03-07

Abstract Objectives This multicentre retrospective study aimed to evaluate differences in drug continuation rates and efficacy between first- second-line use of biological disease-modifying antirheumatic drugs (bDMARDs) Janus kinase inhibitors (JAKi) after failure the initial therapy real-world rheumatoid arthritis (RA) settings. Methods Data from an observational registry patients with RA Japan were analysed, encompassing 5,900 treatment courses (4,046 bDMARD/JAKi-naïve cases 1,854 s-line...

10.1093/rheumatology/keaf157 article EN Lara D. Veeken 2025-03-20

Strongyloidiasis is a gastrointestinal parasitic infection caused by percutaneous with Strongyloides stercoralis. Digestive symptoms such as diarrhea and abdominal pain are the main manifestation, but serious infections septicemia, purulent meningitis, bacterial pneumonia may occur in individuals harboring human T-lymphotropic virus type 1 (HTLV-1) or who immunocompromised. Although coinfection stercoralis HTLV-1 can lead to chronic strongyloidiasis disseminated form of disease, there high...

10.1186/s12879-020-05195-0 article EN cc-by BMC Infectious Diseases 2020-07-02

Biomarkers of disease activity in lupus nephritis (LN) are demand. This is because they may be useful patients who unable to undergo invasive kidney biopsy, as predictors renal function, and for early detection LN recurrence. The focus on the measurement urinary chemokines cytokines, especially biomarkers, which non-invasive simple. In our previous report, we reported that injury molecule-1 (KIM-1) expressed injured tubules number tubular-KIM-expressing positive cells correlates with...

10.1177/09612033221135871 article EN Lupus 2022-10-28

Purpose: We evaluated the clinical responses and radiographic outcomes of 90 patients with rheumatoid arthritis (RA) undergoing continuous or dose-adjusted infliximab treatment over 104 weeks. Patients methods: received 3 mg/kg continuously (the contin group; n=50), dose escalation de-escalation (3, 6, 10 mg/kg) from week 14 adjusted n=40) based on patient's Disease Activity Score in 28 joints (DAS28). The retention rate, response, assessment were determined at 104. Results: groups' rates...

10.2147/btt.s187998 article EN cc-by-nc Biologics 2018-11-01

Abstract Objective Rheumatoid arthritis (RA) affects multiple organ systems, including the esophagus. Moreover, one of major side effects methotrexate (MTX) is gastrointestinal disorders, which are said to affect medication adherence. We investigated rate MTX use, dosage, and use glucocorticoids (GCs) oral non-steroidal anti-inflammatory drugs (NSAIDs) in relation gastroesophageal (GE) symptoms, whether they influence RA disease activity. Methods This study utilized GerdQ questionnaire...

10.1186/s41927-024-00442-2 article EN cc-by BMC Rheumatology 2024-12-23

Psoriasis is an immune-mediated inflammatory disease of the skin, which characterized by epidermal hyperkeratosis and neutrophil infiltration. The interleukin (IL)-17/IL-23 pathway associated cytokines play major roles in pathogenesis exacerbation psoriasis. IL-18/IL-18 receptor (R) α signaling important for Th1 cytokine production differentiation cells; however, its role psoriasis remains unknown. In this study, we investigated effect IL-18Rα-mediated Il18ra-deficient mice (Il18ra-/-)...

10.3389/fmed.2023.1293132 article EN cc-by Frontiers in Medicine 2023-10-27

Objective: Rheumatoid arthritis (RA) treatments have markedly advanced with the introduction of biological agents, e. g., tumor necrosis factor (TNF) inhibitors. TNF inhibitors are demonstrated to be quite effective in combination methotrexate (MTX), and sufficient doses both agents important control RA's disease activity. However, not all RA patients can treated high-dose MTX due contraindications related antimetabolite action or tolerability concerns. In daily practice, this has resulted...

10.3389/fmed.2021.643459 article EN cc-by Frontiers in Medicine 2021-04-21

It is known that the causative diseases of secondary hypertrophic pachymeningitis (HP) include infections, malignant tumors, autoimmune diseases.Although myelodysplastic syndromes (MDS) are often accompanied by certain diseases, HP with MDS rare.We here describe patient complicated and have severe resistance to steroid therapy successfully treated combination corticosteroids 5-Azacytidine (5-Aza).Administration 5-Aza might be a useful therapeutic option for patients refractory MDS.

10.26717/bjstr.2018.10.001932 article EN Biomedical Journal of Scientific & Technical Research 2018-10-24
Coming Soon ...